- Previous Close
1.320 - Open
1.350 - Bid 1.340 x --
- Ask 1.350 x --
- Day's Range
1.300 - 1.350 - 52 Week Range
0.760 - 2.050 - Volume
923,000 - Avg. Volume
2,246,926 - Market Cap (intraday)
1.323B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.270 - Earnings Date Aug 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.97
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
www.ascletis.comRecent News: 1672.HK
View MorePerformance Overview: 1672.HK
Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1672.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1672.HK
View MoreValuation Measures
Market Cap
1.29B
Enterprise Value
-967.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
124.53
Price/Book (mrq)
0.54
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.18%
Return on Equity (ttm)
-10.89%
Revenue (ttm)
10.09M
Net Income Avi to Common (ttm)
-258.47M
Diluted EPS (ttm)
-0.270
Balance Sheet and Cash Flow
Total Cash (mrq)
2.09B
Total Debt/Equity (mrq)
0.41%
Levered Free Cash Flow (ttm)
-223.21M